Cheah, C. Y., Nastoupil, L. J., Neelapu, S. S., Forbes, S. G., Oki, Y., & Fowler, N. H. (2015). Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood.
Stile di citazione ChicagoCheah, Chan Yoon, Loretta J. Nastoupil, Sattva S. Neelapu, Sheryl G. Forbes, Yasuhiro Oki, e Nathan H. Fowler. "Lenalidomide, Idelalisib, and Rituximab Are Unacceptably Toxic in Patients With Relapsed/refractory Indolent Lymphoma." Blood 2015.
Citazione MLACheah, Chan Yoon, et al. "Lenalidomide, Idelalisib, and Rituximab Are Unacceptably Toxic in Patients With Relapsed/refractory Indolent Lymphoma." Blood 2015.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.